Biocon CSR arm wins 'IHW Gold Award for Diseases Screening Initiative of the Year' for 2022

Published On 2023-01-25 04:30 GMT   |   Update On 2023-01-26 04:11 GMT
Advertisement

Bengaluru: Biocon Foundation, the Corporate Social Responsibility (CSR) arm of Biocon Limited, has been awarded the Gold Award in the ‘Diseases Screening Initiative of the Year’ category for its ‘Oral Cancer Screening Program’ by the India Health and Wellness (IHW) Council at the annual IHW Summit & Awards event, held in Mumbai.

Biocon Foundation’s Mission Director Dr Anupama Shetty received the award at the 8th edition of the IHW Summit & Awards, which was co-hosted by the Public Health & Family Welfare Department, Government of Maharashtra, and supported by NITI Aayog.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Managing Trustee, Biocon Foundation, said, “The IHW Council’s ‘Gold Award for Diseases Screening Initiative of the Year’ is a great recognition of the impact Biocon Foundation has made in the early detection and management of oral cancer in the country through its cost-effective, innovative and technology-based screening program. Downstaging oral cancer through early detection is key to alleviate the burden of disease and oral cancer has been a major public health issue in India for several decades. The Foundation’s efforts are leading to improved survival, decreased morbidity and low out-of-pocket expenditure for patients.”

On receiving the award, Dr Anupama Shetty, Mission Director, Biocon Foundation, said, “We are extremely happy to receive the IHW Council’s Gold Award for our Oral Cancer Screening Program, which adopts a unique approach for robust surveillance and monitoring of high-risk groups in population-based and opportunistic screenings. Our mobile health (mHealth) module offers a simple interface that lends itself to effective data capture by health providers at all levels. The initiative has resulted in more than 70,000 screenings in different parts of India, and ~13% of positive detections for Oral Potentially Malignant Disorders (OPMDs) have been reported.”

mHealth-technology-based (mobile health) oral cancer screening program is aimed at addressing and downstaging cancer of the lip and oral cavity, which is the most common cancer among males and the fourth most common cancer among females in India. It accounts for around 30% of all cancers in India, according to GLOBOCAN 2020. The Foundation’s program improves the ability of Frontline Healthcare Providers (FHPs) to prevent and diagnose oral cancer at an early stage in low-resource settings. The capacity building of FHPs in the use of a mobile phone-based app empowers them to capture health data, including intra-oral images. It also connects FHPs to remote specialists for diagnosis. 

Since its inception in 2011, the program has been rolled out in various high-disease-burden areas in Karnataka, Uttar Pradesh, Rajasthan, Delhi, Punjab, Nagaland, and Assam. The Foundation has trained more than 1,000 medical, paramedical, and healthcare workers in using the mHealth technology for oral cancer screening. The program has also led to research publications on the role of community health workers in early detection, use of mHealth and point-of-care technologies, consensus guidelines for the management of head and neck cancers, and OPMDs in leading, peer-reviewed journals such as the Scientific Reports - Nature, Indian Journal of Cancer and others. Biocon Foundation has also forged meaningful partnerships with state governments, tertiary health centres and academic institutions for research and delivery of quality health services at scale. Its partnerships with the Indian Institute of Science (IISc), Bengaluru and the International Institute of Information Technology (IIIT), Hyderabad have led to the development of an AI-based algorithm for the binary classification of cancerous and precancerous lesions. 



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News